Company Overview and News
Globalstar, Inc. (GSAT - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GSAT recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
SDOCQ GSAT BBW SDRPQ AMD SDRXP MPC SD SDRXQ
Intelsat S.A.(I - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 16.8% in the past one-month time frame.
June 12, 2018: Here are four stocks trading with heavy volume among 41 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 1.01 to 1 and on the Nasdaq, advancers led decliners by about 1.2 to 1.
HMY GSAT NGD AVP NGDAF NGD HGMCF
June 11, 2018: Here are four stocks trading with heavy volume among 49 equities making new 52-week lows in Monday’s session. On the NYSE advancers led decliners by about 1.3 to 1 and on the Nasdaq, advancers led decliners by about 1.23 to 1.
HMY DUKH GSAT ADNT DUK HGMCF
June 8, 2018: Here are four stocks trading with heavy volume among 41 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.43 to 1 and on the Nasdaq, advancers led decliners by about 1.31 to 1.
RPCGF GSAT RPC RPCGY TROVW BERY TROV TROVU RES
May 18 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Friday:
GSAT C6L CQP PBBGF T8B PYPL SINGY ENB FUJIF 4901 500470 KR LLOBF VIAB EBBNF CBS VIA ENBBF LLOY CBS.A LNG LYG CBS.WD XRX ENB LLPH LLPK LLPJ TTST LLPE LLPD TATASTEEL TATLY LLPG LLDTF LLD5 LLD7 LLPC LLD6 CPV LLD1 FUJIY SINGF LLD2
May 17 (Reuters) - Mudrick Capital Management LP on Thursday filed a lawsuit against satellite communications company Globalstar Inc over its proposed merger with FiberLight LLC, stating that the terms of the deal valued at $1.65 billion are “wildly unfair.”
Welcome to the Q1 2018 Globalstar, Inc. Earnings Conference Call. My name is John, and I’ll be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note the conference is being recorded.
2017-11-04 - Asif
Mobile Satellite Services Business Globalstar, Inc. (“we,” “us” or the “Company”) provides Mobile Satellite Services (“MSS”) including voice and data communications services globally via satellite. By providing wireless communications services in areas not served or underserved by terrestrial wireless and wireline networks and in circumstances where terrestrial networks are not operational due to natural or man-made disasters, the company seek to meet its customers' increasing desire for connectivity. The company offer voice and data communication services over its network of in-orbit satellites and its active ground stations (“gateways”), which the company refer to collectively as the Globalstar System. The company currently provide the following communications services via satellite. These services are available only with equipment designed to work on its network: two-way voice communication and data transmissions ("Duplex") using mobile or fixed devices; and one-w...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to GSAT / Globalstar, Inc. on message board site Silicon Investor.
|Globalstar Telecommunications Limited GSAT||Globalstar|
|GLOBALSTAR - The New Beginning - GSTRF / GSTRQ|
as of ET